Association of Cutibacterium acnes with human thyroid cancer.

Autor:	Trivedi V; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Noronha V; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Sreekanthreddy P; 4baseCare Oncosolutions Pvt ltd, Institute of Bioinformatics and Applied Biotechnology, Bengaluru, Karnataka, India., Desai S; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, Maharashtra, India., Poojary D; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Varghese L; 4baseCare Oncosolutions Pvt ltd, Institute of Bioinformatics and Applied Biotechnology, Bengaluru, Karnataka, India., Gowda P; 4baseCare Oncosolutions Pvt ltd, Institute of Bioinformatics and Applied Biotechnology, Bengaluru, Karnataka, India., Butle A; Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, Maharashtra, India., Mishra R; Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, Maharashtra, India., Bal M; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Mittal N; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Rane S; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Kane S; Consultant Onco-pathologist, Jaslok Hospital, Mumbai, Maharashtra, India., Basu S; Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India., Patil V; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Menon N; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Singh AK; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Chaturvedi P; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Head and Neck Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India., Chandrani P; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Medical oncology molecular laboratory, Tata Memorial Hospital, Mumbai, Maharashtra, India.; Centre for Computational Biology, Bioinformatics and Crosstalk Lab, Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, Maharashtra, India., Choughule A; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Veldore V; 4baseCare Oncosolutions Pvt ltd, Institute of Bioinformatics and Applied Biotechnology, Bengaluru, Karnataka, India., Prabhash K; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Dutt A; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, Maharashtra, India.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Nov 10; Vol. 14, pp. 1152514. Date of Electronic Publication: 2023 Nov 10 (Print Publication: 2023).
DOI:	10.3389/fendo.2023.1152514
Abstrakt:	Introduction: The diverse subtypes of thyroid carcinoma have distinct clinical outcomes despite a comparable spectrum of underlying genetic alterations. Beyond genetic alterations, sparse efforts have been made to characterize the microbes associated with thyroid cancer. In this study, we examine the microbial profile of thyroid cancer. Methods: We sequenced the whole transcriptome of 70 thyroid cancers (40 papillary and 30 anaplastic). Using Infectious Pathogen Detector IPD 2.0, we analysed the relative abundance of 1060 microbes across 70 tumours from patients with thyroid cancer against 118 tumour samples from patients with breast, cervical, colorectal, and tongue cancer. Results: Our analysis reveals a significant prevalence of Cutibacterium acnes in 58.6% thyroid cancer samples compared to other cancer types ( p=0.00038 ). Immune cell fraction analysis between thyroid cancer samples with high and low Cutibacterium loads identify enrichment of immunosuppressive cells, including Tregs ( p=0.015 ), and other anti-inflammatory cytokines in the tumour microenvironment, suggesting an immune evasion/immunosuppression milieu is associated with the infection. A higher burden of Cutibacterium acnes was also found to be associated with poor survival defining a distinct sub-group of thyroid cancer. Conclusion: Cutibacterium acnes is associated with immune suppression and poor prognosis in a subpopulation of thyroid cancer. This study may help design novel therapeutic measures involving appropriate antibiotics to manage the disease better. Competing Interests: PS, LV, PG, and VV were employed by 4baseCare Oncosolutions Pvt ltd. VT has been supported by a Prime Minister’s Research Fellowship (PMRF) for doctoral research provided by the Government of India - Science and Engineering Research Board (SERB) & Confederation of Indian Industry (CII) in conjunction with NATCO Pharmaceutical Ltd, Hyderabad, India. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study was financed via a collaborative basic research project involving the Tata Memorial Centre, an autonomous grant-in-aid institution under the aegis of the Department of Atomic Energy (DAE), Government of India, and 4baseCare Oncosolutions Pvt Ltd, a commercial entity. This collaboration was established through an institutional Memorandum of Understanding (MOU). 4baseCare Oncosolutions Pvt Ltd had the following involvement with the study: DNA/RNA extraction from FFPE block, whole exome DNA/RNA library preparation, and sequencing on the Illumina platform to generate sequencing data, which was subsequently independently analyzed by the authors of the study at the Tata Memorial Centre. No financial transactions took place between 4baseCare Oncosolutions Pvt Ltd and the Tata Memorial Centre. The study was also supported by DBT-Virtual National Cancer Institute (VNCI) [BT/MED/30/VNCI-Hr-BRCA/2015]. None of the funders had any role in the analysis and interpretation of data in the study. (Copyright © 2023 Trivedi, Noronha, Sreekanthreddy, Desai, Poojary, Varghese, Gowda, Butle, Mishra, Bal, Mittal, Rane, Kane, Basu, Patil, Menon, Singh, Chaturvedi, Chandrani, Choughule, Veldore, Prabhash and Dutt.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu